NCT07737977Not yet recruiting
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 27 Jul 2026
- Start date
- Aug 2026
- Primary completion date
- Feb 2029
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT07737977
What you commit to
- Study type: Observational
- Planned participants: 200
- From Aug 2026 to the primary completion date, Feb 2029
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Refusal to participate.
- Individuals deprived of liberty (Article L1121-6), including those subject to judicial or administrative decisions or involuntary hospitalization.
- Adults under legal protection (guardianship, curatorship, or judicial protection measures) (Article L1121-8).
- Individuals not affiliated with, or not beneficiaries of, a French social security scheme (Article L1121-8-1).
- Individuals participating in another research study with an ongoing exclusion period (Article L1121-12).
Who the study is looking for
- Age greater than 18 years.
- Male and female patients with ALS diagnosed according to the El Escorial diagnostic criteria.
- Sporadic or familial ALS cases.
- Spinal-onset or bulbar-onset ALS cases.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Montpellier University Hospital Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.